menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

VTGN / VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2022 Results - Earnings Call Transcript

VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2022 Results - Earnings Call Transcript
VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2022 Earnings Conference Call June 23, 2022 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies LLC Lachlan Hanbury-Brown - William Blair & Company, LLC Luke Herrmann - Robert W. Baird & Co. Michael Okunewitch - Maxim Group LLC Operator Greetings, welcome to the VistaGen Therapeutics' 2022 Fiscal Year-End Results Conference Call. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Vistagen

Therapeutics

Inc

VTGN

Shawn

Singh

2022

Results

Therapeutics

vtgn

Earnings

Transcript

Stock

Posted: Jun 23 2022, 22:14
Author Name: Seeking Alpha
Views: 111858

VTGN News  

Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript

By Seeking Alpha
August 13, 2023

Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript

Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Mark Flather - VP of IR Sh more_horizontal

Outperforming Biotech Pops on Shareholder Buzz

By Schaeffers Research
August 10, 2023

Outperforming Biotech Pops on Shareholder Buzz

Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Mast more_horizontal

Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?

By InvestorPlace
August 7, 2023

Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?

Vistagen Therapeutics (NASDAQ: VTGN ) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer more_horizontal

VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here's Why

By PennyStocks
August 7, 2023

VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here's Why

Are you looking for penny stocks to buy? Are you grappling with the push and pull of skeptics saying penny stocks aren't worth it or penny stocks are more_horizontal

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

By Business Wire
June 27, 2023

Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming more_horizontal

VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call Transcript

By Seeking Alpha
February 10, 2023

VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call Transcript

VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2023 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Mark Flather - Vice Presi more_horizontal

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

By Zacks Investment Research
February 7, 2023

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. D more_horizontal

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

By Business Wire
February 6, 2023

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treat more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: